Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAK4 | O96013 | 3/20 | 0.40 |
| ▸ | IGF1R | P08069 | 3/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.36 |
| ▸ | NTRK1 | P04629 | 5/20 | 0.36 |
| ▸ | LMNA | P02545 | 4/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.34 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1887219 | 1.00 | PAK4 (0.40) | PAK4IGF1RSMN1; SMN2NTRK1LMNA | |
| SCHEMBL1894384 | 0.91 | IGF1R (0.38) | PAK4IGF1RNTRK1NTRK3NTRK2 | |
| SCHEMBL1889566 | 0.90 | PAK4 (0.40) | PAK4IGF1RNTRK1LMNAALDH1A1 | |
| SCHEMBL1883716 | 0.90 | PAK4 (0.40) | PAK4IGF1RNTRK1LMNAALDH1A1 | |
| SCHEMBL1888187 | 0.90 | IGF1R (0.38) | PAK4IGF1RNTRK1NTRK3NTRK2 | |
| SCHEMBL1893497 | 0.89 | PAK4 (0.41) | PAK4IGF1RSMN1; SMN2NTRK1LMNA | |
| SCHEMBL1891495 | 0.89 | PAK4 (0.41) | PAK4IGF1RSMN1; SMN2NTRK1LMNA | |
| SCHEMBL1886049 | 0.89 | NTRK1 (0.42) | PAK4IGF1RSMN1; SMN2NTRK1LMNA | |
| SCHEMBL1892245 | 0.89 | NTRK1 (0.42) | PAK4IGF1RSMN1; SMN2NTRK1LMNA | |
| SCHEMBL1890739 | 0.88 | IGF1R (0.50) | PAK4IGF1RSMN1; SMN2LMNANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110230470-A1 | SUBSTITUTED PYRAZOLO[4,3-C]PYRIDINE DERIVATIVES ACTIVE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2011-09-22 | — | — | US | disclosed |
| US-7947686-B2 | Substituted pyrazolo[4,3-c]pyridine derivatives active as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2011-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230470-A1 | SUBSTITUTED PYRAZOLO[4,3-C]PYRIDINE DERIVATIVES ACTIVE AS KINASE INHIBITORS | MAP3K3, MAP3K1, MAP3K19 | PAK4 44/4885IGF1R 760/4885SMN1; SMN2 3711/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.